(CTKB) Cytek Biosciences - Overview
Stock: Flow Cytometer, Cell Sorter, Reagents, Software, Imaging Analyzer
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 69.0% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.07 |
| Alpha | -38.65 |
| Character TTM | |
|---|---|
| Beta | 1.232 |
| Beta Downside | 0.891 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.38% |
| CAGR/Max DD | -0.36 |
Description: CTKB Cytek Biosciences December 28, 2025
Cytek Biosciences, Inc. (NASDAQ:CTKB) develops and sells advanced cell-analysis instruments-including the Aurora full-spectrum cell sorter, Northern Lights analyzers, Amnis ImageStream imaging flow cytometers, Guava Muse and EasyCyte flow cytometers, and Orion reagent-cocktail preparation systems-plus associated reagents (e.g., cFluor-conjugated antibodies) and software (SpectroFlo) that streamline workflow from quality control to data analysis.
The company’s customer base spans pharmaceutical and biopharma firms, academic research institutions, and clinical research organizations, with sales channels that combine a direct North-American sales force and regional distributors in Europe, Latin America, the Middle East, and the Asia-Pacific.
In FY 2023 Cytek reported revenue of roughly $70 million, up about 30 % year-over-year, and maintained an operating margin near 20 % thanks to the high-value, recurring nature of consumables and software licenses. The global flow-cytometry market is projected to grow at a CAGR of ~10 % through 2030, driven by expanding immunotherapy pipelines and the need for high-parameter single-cell profiling in both drug discovery and clinical diagnostics.
For a deeper quantitative dive, the ValueRay platform offers granular financial models and peer benchmarks for CTKB.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -12.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -7.04 > 1.0 |
| NWC/Revenue: 159.2% < 20% (prev 162.7%; Δ -3.55% < -1%) |
| CFO/TA -0.00 > 3% & CFO -1.92m > Net Income -12.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (127.5m) vs 12m ago -3.94% < -2% |
| Gross Margin: 53.46% > 18% (prev 0.55%; Δ 5291 % > 0.5%) |
| Asset Turnover: 39.92% > 50% (prev 40.96%; Δ -1.04% > 0%) |
| Interest Coverage Ratio: -15.74 > 6 (EBITDA TTM -18.1m / Interest Expense TTM 1.89m) |
Altman Z'' 2.85
| A: 0.63 (Total Current Assets 388.5m - Total Current Liabilities 75.2m) / Total Assets 494.9m |
| B: -0.12 (Retained Earnings -57.7m / Total Assets 494.9m) |
| C: -0.06 (EBIT TTM -29.8m / Avg Total Assets 493.1m) |
| D: -0.49 (Book Value of Equity -56.7m / Total Liabilities 116.3m) |
| Altman-Z'' Score: 2.85 = A |
Beneish M -2.84
| DSRI: 1.20 (Receivables 61.7m/52.6m, Revenue 196.8m/201.2m) |
| GMI: 1.03 (GM 53.46% / 54.92%) |
| AQI: 1.06 (AQ_t 0.16 / AQ_t-1 0.15) |
| SGI: 0.98 (Revenue 196.8m / 201.2m) |
| TATA: -0.02 (NI -12.8m - CFO -1.92m) / TA 494.9m) |
| Beneish M-Score: -2.84 (Cap -4..+1) = A |
What is the price of CTKB shares?
Over the past week, the price has changed by -10.60%, over one month by -19.02%, over three months by -1.54% and over the past year by -20.32%.
Is CTKB a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CTKB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6 | 34.2% |
| Analysts Target Price | 6 | 34.2% |
| ValueRay Target Price | 3.5 | -21.5% |
CTKB Fundamental Data Overview February 03, 2026
P/S = 3.2481
P/B = 1.6922
Revenue TTM = 196.8m USD
EBIT TTM = -29.8m USD
EBITDA TTM = -18.1m USD
Long Term Debt = 655.0k USD (from longTermDebt, last quarter)
Short Term Debt = 12.9m USD (from shortTermDebt, last quarter)
Debt = 35.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -58.1m USD (from netDebt column, last quarter)
Enterprise Value = 412.8m USD (639.3m + Debt 35.2m - CCE 261.7m)
Interest Coverage Ratio = -15.74 (Ebit TTM -29.8m / Interest Expense TTM 1.89m)
EV/FCF = -69.91x (Enterprise Value 412.8m / FCF TTM -5.90m)
FCF Yield = -1.43% (FCF TTM -5.90m / Enterprise Value 412.8m)
FCF Margin = -3.00% (FCF TTM -5.90m / Revenue TTM 196.8m)
Net Margin = -6.51% (Net Income TTM -12.8m / Revenue TTM 196.8m)
Gross Margin = 53.46% ((Revenue TTM 196.8m - Cost of Revenue TTM 91.6m) / Revenue TTM)
Gross Margin QoQ = 52.69% (prev 52.34%)
Tobins Q-Ratio = 0.83 (Enterprise Value 412.8m / Total Assets 494.9m)
Interest Expense / Debt = 1.40% (Interest Expense 494.0k / Debt 35.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -23.5m (EBIT -29.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.17 (Total Current Assets 388.5m / Total Current Liabilities 75.2m)
Debt / Equity = 0.09 (Debt 35.2m / totalStockholderEquity, last quarter 378.6m)
Debt / EBITDA = 3.21 (negative EBITDA) (Net Debt -58.1m / EBITDA -18.1m)
Debt / FCF = 9.84 (negative FCF - burning cash) (Net Debt -58.1m / FCF TTM -5.90m)
Total Stockholder Equity = 382.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.60% (Net Income -12.8m / Total Assets 494.9m)
RoE = -3.35% (Net Income TTM -12.8m / Total Stockholder Equity 382.9m)
RoCE = -7.77% (EBIT -29.8m / Capital Employed (Equity 382.9m + L.T.Debt 655.0k))
RoIC = -6.05% (negative operating profit) (NOPAT -23.5m / Invested Capital 389.1m)
WACC = 9.97% (E(639.3m)/V(674.5m) * Re(10.46%) + D(35.2m)/V(674.5m) * Rd(1.40%) * (1-Tc(0.21)))
Discount Rate = 10.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.22%
Fair Price DCF = unknown (Cash Flow -5.90m)
EPS Correlation: -19.94 | EPS CAGR: -7.91% | SUE: 0.13 | # QB: 0
Revenue Correlation: 60.34 | Revenue CAGR: 8.21% | SUE: 0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.01 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-200.0% | Growth Revenue=+5.4%